BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270129
DTSTAMP:20260925T061157Z
CREATED:20260925T060703Z
LAST-MODIFIED:20260925T061157Z
UID:44399-1800921600-1801180799@www.pharmajournalist.com
SUMMARY:Muscular Disorders Drug Development Summit
DESCRIPTION:Muscular Disorders Drug Development Summit | January 26-28\, 2027 | Boston\, MA \nThe muscular disease field is entering a pivotal new chapter. Following a year of significant debate around Sarepta’s Elevidys\, the industry is rapidly evolving as a new wave of gene therapies\, RNA medicines\, stem cell therapies\, and small molecules advance through development. With anticipated regulatory milestones from companies including Regenxbio\, Capricor\, and Avidity Biosciences\, alongside growing investment and renewed pharmaceutical interest\, momentum has never been stronger across muscular dystrophies\, Pompe disease\, and related myopathies. \nThe inaugural Muscular Disorders Drug Development Summit is the only industry-focused forum dedicated to helping biopharma leaders accelerate the translation\, clinical development\, and delivery of next-generation therapies for muscle disorders. \nBe the first to access the newly launched event program. \nAcross three days of expert-led presentations\, interactive discussion\, and dedicated networking\, attendees will: \n\nDiscover lessons learned from approved and late-stage muscular disease therapies\nExplore emerging modalities beyond traditional gene therapy\nAdvance biomarker strategies and functional outcome assessments\nInnovate targeted delivery approaches to improve efficacy and reduce off-target effects\nLeverage real-world data to identify meaningful\, patient-relevant endpoints\nBuild partnerships that can accelerate clinical and commercial success\n\nJoin 60+ industry experts and leading organizations including Servier\, Dyne Therapeutics\, Sanofi\, Biogen\, and Avidity Biosciences for three days of collaboration focused on overcoming the biggest challenges in muscular disorder drug development. \nWhether you’re advancing therapies for DMD\, FSHD\, DM\, LGMD\, Pompe disease\, or other rare muscle disorders\, this is the must-attend meeting to benchmark strategies\, forge new partnerships\, and help bring transformative treatments to patients faster. \nExplore the Full Agenda | Register Your Place
URL:https://www.pharmajournalist.com/event/muscular-disorders-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270129
DTSTAMP:20261002T121356Z
CREATED:20261002T121356Z
LAST-MODIFIED:20261002T121356Z
UID:44484-1800921600-1801180799@www.pharmajournalist.com
SUMMARY:2nd Non-Opioid Pain Therapeutics Summit
DESCRIPTION:One year on from Vertex Pharmaceuticals’ milestone JOURNAVX® approval\, making history as the first new class of pain medicine in decades\, non-opioid pain R&D has skyrocketed as one of biopharma’s hottest areas for innovation and investment\, projected to hit $124bn by 2034. \nBringing together 150+ senior leaders across pain biology\, drug discovery\, translational science\, clinical development\, medical affairs\, business development\, venture capital\, and patient advocacy\, the 2nd Non-Opioid Pain Therapeutics Summit is the ultimate forum for drug developers to advance the next generation of pain medicines. Join experts from Vertex Pharmaceuticals\, Eli Lilly\, AbbVie\, Grünenthal\, Xenon Pharmaceuticals\, Levicept\, Tonix Pharma\, Maxona Pharmaceuticals\, 4E Therapeutics\, NIH\, Harvard Medical School\, and leading investment firms to explore emerging mechanisms\, new clinical data\, trial design innovations\, placebo mitigation strategies\, translational models\, patient-centered development approaches\, and the investment trends shaping the future of pain therapeutics. \nTo know more visit: https://ter.li/9cl7g1gn
URL:https://www.pharmajournalist.com/event/2nd-non-opioid-pain-therapeutics-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR